Dupixent Denied? Appeal Guide for Eczema, Asthma, and EoE Patients

You opened the letter (or the portal notification, or the email) and there it is: denied. Your doctor prescribed Dupixent because the treatments you've already tried aren't cutting it. And now your insurance company is telling you no.

Take a breath. You're not out of options. Not even close.

Dupixent (dupilumab), manufactured by Regeneron and Sanofi, is one of the most broadly approved biologic medications available today. It carries FDA approval across eight distinct conditions, from moderate-to-severe eczema in babies as young as six months old to COPD in adults. And yet, insurance denials for Dupixent remain stubbornly common. The reasons range from step therapy requirements to cost concerns (the list price runs $36,000 or more per year) to insurers demanding more documentation of how severe your condition really is.

Here's the thing most patients don't know: according to KFF research, only about 1% of denied claims ever get appealed. But among those who do appeal internally, roughly 44% succeed. That gap between "almost nobody appeals" and "nearly half of appeals win" represents a massive, untapped opportunity. This guide is designed to help you take it.

What follows is a condition-by-condition breakdown of why Dupixent gets denied and how to build an appeal that actually works. Whether you're dealing with eczema, asthma, eosinophilic esophagitis, nasal polyps, or one of Dupixent's newer indications, you'll find actionable steps here.

What Dupixent Is Approved to Treat (All 8 Indications)

One of Dupixent's biggest strengths, and one of your strongest appeal arguments, is just how many conditions it's FDA-approved for. As of 2024 and 2025, Dupixent has the broadest indication range of almost any biologic on the market. Here's the full list:

• •Atopic Dermatitis (Eczema): adults and children 6 months and older with moderate-to-severe disease not adequately controlled by topical therapies
• •Asthma: moderate-to-severe eosinophilic phenotype or oral corticosteroid-dependent asthma in adults and children 6 years and older
• •Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): adults
• •Eosinophilic Esophagitis (EoE): patients 1 year and older (expanded from ages 12+ down to ages 1 through 11 in January 2024)
• •Prurigo Nodularis (PN): adults
• •Chronic Spontaneous Urticaria (CSU): patients 12 years and older; the first new targeted therapy for CSU in over a decade
• •Bullous Pemphigoid (BP): adults; the first and only targeted therapy approved for this condition
• •COPD: adults with eosinophilic phenotype; the first biologic ever approved for COPD

Why does this matter for your appeal? Because the breadth of Dupixent's approvals demonstrates the strength and depth of its clinical evidence base. When an insurer denies Dupixent, they're pushing back against a medication that the FDA has reviewed and approved across eight separate conditions, a level of regulatory confidence that very few biologics can match.

Why Insurance Companies Deny Dupixent

Before you can fight a denial, you need to understand exactly why it happened. Check your denial letter carefully because it should include a specific reason. Most Dupixent denials fall into one of these categories:

• •Step therapy / "fail first" requirements: Your insurer wants proof that you tried (and failed) cheaper treatments before approving Dupixent. This is the single most common reason for denial.
• •Prior authorization not completed or insufficient: Your provider didn't submit the right forms or didn't include enough clinical documentation.
• •Medical necessity not established: The insurer doesn't believe your condition is severe enough to warrant a biologic, or the documentation submitted doesn't demonstrate severity clearly.
• •Cost and formulary restrictions: Dupixent may not be on your plan's preferred drug list, or your plan may require you to try a different biologic first.
• •Off-label or unsupported indication: If you're being prescribed Dupixent for a use that doesn't match one of the eight FDA-approved indications, the bar for approval is significantly higher.

Your denial letter is required to tell you the specific reason. Read it carefully and identify which category applies. That reason will shape your entire appeal strategy.

Step Therapy: The Biggest Hurdle (and How to Clear It)

Step therapy, sometimes called "fail first," is the number one reason Dupixent gets denied. The concept is straightforward: your insurer requires you to try less expensive treatments and document that they didn't work before they'll approve a biologic. The problem is that these protocols can delay access to the medication your doctor already knows you need, sometimes by months.

The specific steps vary by condition. Here's what insurers typically require:

Step Therapy for Atopic Dermatitis (Eczema)

• •Step 1: Topical corticosteroids (various potencies)
• •Step 2: Topical calcineurin inhibitors (tacrolimus, pimecrolimus)
• •Step 3: Systemic immunosuppressants (methotrexate, cyclosporine, mycophenolate)
• •Step 4: Dupixent (or another biologic)

Step Therapy for Asthma

• •Step 1: Inhaled corticosteroids (ICS)
• •Step 2: ICS + long-acting beta-agonists (LABA)
• •Step 3: Other biologics may be required first, depending on your plan
• •Step 4: Dupixent

Step Therapy for CRSwNP (Nasal Polyps)

• •Step 1: Intranasal corticosteroids
• •Step 2: May require documented history of sinus surgery
• •Step 3: Dupixent

Step Therapy for EoE (Eosinophilic Esophagitis)

• •Step 1: Proton pump inhibitor (PPI) therapy
• •Step 2: Dupixent

And here's something many patients don't realize: at least 30 states have enacted step therapy reform laws. These laws typically allow you to request an exception if you've already tried the required medications, if the required medications are contraindicated for you, or if delaying treatment would cause irreversible harm. Check whether your state has a step therapy override law because it could change the entire landscape of your appeal.

Appealing a Dupixent Denial for Atopic Dermatitis (Eczema)

Atopic dermatitis was Dupixent's first FDA-approved indication, and the clinical evidence base here is deep. Dupixent is approved for adults and children as young as six months old with moderate-to-severe atopic dermatitis that is not adequately controlled by topical prescription therapies.

When building your appeal for eczema, focus on these key elements:

• •Document the severity of your condition. Validated scoring tools like EASI (Eczema Area and Severity Index), SCORAD, or BSA (Body Surface Area) percentage give your appeal objective, measurable evidence that your eczema is moderate-to-severe. Ask your dermatologist to include these scores.
• •Show that topical therapies have failed. List every topical corticosteroid and calcineurin inhibitor you've tried, with dates, durations, and outcomes. If a medication caused side effects (like skin thinning from prolonged steroid use), document that too.
• •If you've tried systemic immunosuppressants and they failed or caused adverse effects, document this thoroughly. Many patients can't tolerate methotrexate or cyclosporine long-term due to organ toxicity risks, and this is a strong argument for Dupixent.
• •Emphasize functional impact. How does your eczema affect sleep, work, school, daily activities, and mental health? Insurance reviewers respond to documentation of real-world impairment.
• •Include photographs if possible. Clinical photos showing the extent and severity of affected skin areas can be powerfully persuasive.

For children, the appeal may carry additional weight. Parents can document missed school days, sleep disruption, impact on development, and the risks of long-term immunosuppressant use in a growing child. The FDA approved Dupixent for children as young as 6 months precisely because the benefit-risk profile supports it in pediatric patients.

Appealing a Dupixent Denial for Asthma

Dupixent is FDA-approved for moderate-to-severe eosinophilic asthma and oral corticosteroid-dependent asthma in adults and children 6 years and older. This is a specific subset of asthma patients. Not everyone with asthma qualifies for Dupixent, and your appeal needs to clearly demonstrate that you do.

Key evidence for an asthma-related Dupixent appeal:

• •Eosinophil levels. Blood eosinophil counts are central to demonstrating that you have the eosinophilic phenotype Dupixent is designed to treat. Make sure recent lab results are included.
• •Exacerbation history. Document the number of asthma exacerbations, ER visits, hospitalizations, and courses of oral corticosteroids over the past 12 months. A pattern of frequent exacerbations despite current therapy is a compelling argument.
• •Current medication regimen. Show that you're already on high-dose inhaled corticosteroids plus a long-acting beta-agonist (and possibly other controllers) and your asthma is still not controlled.
• •Oral corticosteroid dependence. If you require maintenance oral steroids to control your asthma, document this clearly. Chronic oral corticosteroid use carries serious long-term risks (osteoporosis, diabetes, adrenal insufficiency), and Dupixent may reduce or eliminate the need for them.
• •Pulmonary function tests. FEV1 measurements and trends over time help demonstrate that your lung function is compromised despite current treatment.

One thing to be aware of: some insurance plans require you to try a different asthma biologic before approving Dupixent. If this applies to you, you'll need to either document that you've tried the alternative and it didn't work, or argue for a step therapy exception based on your specific clinical profile.

Appealing a Dupixent Denial for Eosinophilic Esophagitis (EoE)

EoE is a condition that can be difficult to treat and genuinely miserable to live with. Difficulty swallowing, food impaction, chest pain, reflux-like symptoms that don't respond to reflux medications. The impact on quality of life is significant. Dupixent is approved for EoE patients 1 year and older, with the pediatric expansion (ages 1 through 11) approved in January 2024.

For EoE appeals specifically:

• •Document PPI failure. The standard step therapy for EoE requires a trial of proton pump inhibitor therapy first. If you've tried a PPI and your symptoms persisted or your eosinophil counts remained elevated on follow-up biopsy, that's your primary step therapy argument.
• •Include endoscopy and biopsy results. Eosinophil counts per high-power field from esophageal biopsies are the gold standard for diagnosing and monitoring EoE. Include results from before and after any attempted treatments.
• •Document dietary elimination trial results, if applicable. Some patients try elimination diets before medical therapy. If you've attempted this and it was insufficient, include that history.
• •Emphasize complications and risks. Food impactions requiring emergency intervention, esophageal strictures, weight loss, and nutritional deficiencies all strengthen a medical necessity argument.
• •For pediatric patients, document growth impact, feeding difficulties, and the effect on school and social development.

Appealing a Dupixent Denial for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Nasal polyps can be debilitating in ways that don't always get taken seriously. Loss of smell. Chronic congestion. Facial pressure. Recurrent sinus infections. The inability to breathe through your nose. If you've already been through sinus surgery and the polyps came back, Dupixent might be exactly what you need.

For CRSwNP appeals:

• •Document failure of intranasal corticosteroids. This is typically the first step in the step therapy ladder. Show what you've tried, for how long, and that it wasn't enough.
• •Include surgical history. If you've had sinus surgery (especially more than once) and polyps have recurred, this is a powerful argument that you need a systemic therapy, not another round of the same treatments.
• •Provide nasal polyp scores and CT scan findings. Objective measures of polyp burden help demonstrate severity.
• •Document impact on smell, breathing, sleep quality, and frequency of sinus infections. The day-to-day burden of CRSwNP is often undertold in medical records.

Newer Indications: PN, CSU, Bullous Pemphigoid, and COPD

Dupixent's more recent approvals for prurigo nodularis, chronic spontaneous urticaria, bullous pemphigoid, and COPD deserve special mention because denials for newer indications can be even more common. Insurers sometimes lag behind FDA approvals when updating their coverage criteria and formularies.

A few notes specific to these conditions:

• •Prurigo Nodularis (PN): Document the severity and distribution of nodules, the intensity of itching (itch severity scores like the WI-NRS can help), and the failure of topical therapies and other systemic treatments.
• •Chronic Spontaneous Urticaria (CSU): Dupixent is the first new targeted therapy for CSU in over a decade. If you've tried antihistamines at escalated doses and potentially omalizumab without adequate control, document each therapy and its outcome.
• •Bullous Pemphigoid (BP): As the first and only targeted therapy approved for BP, Dupixent fills a genuine gap. Document blister severity, affected body surface area, the failure of topical and systemic corticosteroids, and any steroid-related side effects.
• •COPD (eosinophilic phenotype): As the first biologic approved for COPD, there may be limited payer experience with this indication. Include blood eosinophil counts, exacerbation history, current triple inhaler therapy documentation, and pulmonary function test results.

How to Build Your Dupixent Appeal Step by Step

Regardless of which condition you're appealing for, the mechanics of the appeal process are largely the same. Here's how to approach it:

1. Read Your Denial Letter Carefully

Your denial letter must include the specific reason for denial, the clinical criteria your insurer used, instructions for how to appeal, and the deadline. Don't miss the deadline. Most plans give you 180 days for an internal appeal, but some give less. Mark it on your calendar the day you receive the letter.

2. Gather Your Medical Documentation

This is where appeals are won or lost. You need:

• •Complete medical records showing your diagnosis and treatment history
• •Documentation of every prior therapy tried, including drug names, dosages, dates, duration, and outcomes
• •Lab results (eosinophil counts, allergy panels, biopsies, pulmonary function tests, and whatever else is relevant to your condition)
• •Objective severity scores (EASI for eczema, nasal polyp scores, eosinophil counts per HPF for EoE, etc.)
• •Clinical photos if applicable
• •Documentation of how your condition affects daily life, work, school, and mental health

3. Get a Letter of Medical Necessity from Your Doctor

This letter is the backbone of your appeal. Your prescribing physician should write a detailed letter explaining why Dupixent is medically necessary for your specific situation. The letter should address the insurer's denial reason directly, explain why alternative treatments are inadequate or contraindicated, cite relevant clinical evidence, and describe the likely consequences of not receiving treatment.

A strong letter of medical necessity isn't generic. It tells your story: what you've been through, what you've tried, why those treatments fell short, and why Dupixent is the right next step for you specifically.

4. Write Your Appeal Letter

You can (and should) also write your own appeal letter as the patient. Keep it clear and factual. Include your name, policy number, claim number, and the date of denial. State that you are appealing the denial of Dupixent and explain why. Reference the medical documentation you're including. You don't need to use legal language. Just be honest and specific about how your condition affects your life and why you need this medication.

5. Submit and Track

Submit your appeal by the method specified in your denial letter (often fax, mail, or an online portal). Keep copies of everything. Note the date you submitted, and follow up if you don't receive a response within the timeframe required (typically 30 days for non-urgent internal appeals, 72 hours for urgent/expedited appeals).

If you'd rather not navigate this process alone, Appealio can help you organize your documentation and build your appeal letter. But whether you use a service or do it yourself, the important thing is that you actually file the appeal. Too many patients give up at the denial stage.

Your Legal Right to Appeal

Under the Affordable Care Act, you have a guaranteed right to appeal any insurance denial. This isn't a favor your insurer is granting you. It's the law. Here's what you're entitled to:

• •Internal appeal: Your insurer must review the denial using a different reviewer than the one who made the original decision.
• •External review: If your internal appeal is denied, you have the right to an independent external review by a third party who has no connection to your insurance company. The external reviewer's decision is binding on the insurer.
• •Expedited review: If your health is in immediate jeopardy, you can request an expedited appeal with a faster turnaround.

Don't skip the internal appeal. Even if you think it won't work, completing the internal appeal process is usually required before you can request an external review. And remember, about 44% of internal appeals succeed. The odds are better than most people expect.

Step Therapy Override Laws: Know Your State's Rules

This is one of the most underused tools in the appeals toolkit. At least 30 states have enacted step therapy reform laws that give patients the right to request exceptions to fail-first requirements. These laws vary by state, but they generally allow exceptions when:

• •You've already tried and failed the required step therapy medications
• •The required medication is contraindicated for you (due to allergies, drug interactions, or other medical reasons)
• •The required medication is expected to cause irreversible harm
• •You're currently stable on the prescribed medication and switching would be disruptive
• •The required medication is not in the best interest of the patient based on clinical evidence

If you live in a state with a step therapy override law, reference it explicitly in your appeal. Your doctor can request a step therapy exception, and the insurer is legally required to consider it. Organizations like the Arthritis Foundation and the National Psoriasis Foundation maintain updated information on which states have these protections.

Common Appeal Mistakes to Avoid

After seeing what works and what doesn't in insurance appeals, a few patterns stand out. Avoid these mistakes:

• •Not appealing at all. This is the biggest one. A denial is not a final answer. It's the start of a process.
• •Missing the deadline. Mark it on your calendar. Set a reminder. Don't let administrative inertia cost you your appeal rights.
• •Submitting without sufficient documentation. A one-paragraph appeal letter without medical records won't cut it. The more thorough your documentation, the stronger your case.
• •Not addressing the specific denial reason. If you were denied for step therapy, your appeal needs to focus on step therapy. If you were denied for medical necessity, focus on severity and functional impact. Don't send a generic letter.
• •Leaving it entirely to your doctor's office. Your doctor's support is crucial, but don't assume their office will handle everything. Stay involved, follow up, and submit your own patient appeal letter alongside theirs.

What If Your Internal Appeal Is Denied?

It happens. But a denied internal appeal is still not the end of the road.

Your next step is to request an external review. An independent reviewer, someone with no ties to your insurance company, will evaluate your case from scratch. External reviewers are typically physicians who specialize in the relevant medical area. And here's the key part: their decision is legally binding on your insurer. If the external reviewer says your Dupixent should be covered, your insurance company has to cover it.

You can also explore other avenues in parallel:

• •Manufacturer assistance programs: Regeneron/Sanofi offer patient assistance programs for Dupixent, including a copay card program and, for eligible patients, the medication at no cost.
• •State insurance department complaints: Filing a complaint with your state's Department of Insurance can sometimes prompt action.
• •Peer-to-peer review: Your doctor can request a phone call with the insurer's medical director to discuss your case directly.
• •If you're covered through an employer plan, your HR department may be able to advocate on your behalf with the insurer.

Putting It All Together

A Dupixent denial can feel overwhelming, especially when you're already dealing with a condition that's affecting your health and quality of life every single day. But the appeal process exists for a reason, and it works more often than most people realize.

Here's the short version of everything we've covered:

• •Read your denial letter and identify the specific reason
• •Gather comprehensive medical documentation
• •Get a detailed letter of medical necessity from your doctor
• •Write your own patient appeal letter
• •Reference step therapy override laws if applicable
• •Submit on time and keep copies of everything
• •If internal appeal fails, request external review

If you want help pulling your appeal together, Appealio can walk you through the documentation process and help you build a structured appeal letter tailored to your condition and denial reason. But tools or no tools, the most important step is simply deciding to appeal.

You deserve access to the treatment your doctor prescribed. The fact that you're reading this guide means you're already doing the work. Keep going. The system is complicated and frustrating, but it's not unbeatable. Patients win these appeals every day, and you can too.